Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

63 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
PBRM1 mutations might render a subtype of biliary tract cancers sensitive to drugs targeting the DNA damage repair system.
Zimmer K, Kocher F, Untergasser G, Kircher B, Amann A, Baca Y, Xiu J, Korn WM, Berger MD, Lenz HJ, Puccini A, Fontana E, Shields AF, Marshall JL, Hall M, El-Deiry WS, Hsiehchen D, Macarulla T, Tabernero J, Pichler R, Khushman M, Manne U, Lou E, Wolf D, Sokolova V, Schnaiter S, Zeimet AG, Gulhati P, Widmann G, Seeber A. Zimmer K, et al. Among authors: hsiehchen d. NPJ Precis Oncol. 2023 Jul 3;7(1):64. doi: 10.1038/s41698-023-00409-5. NPJ Precis Oncol. 2023. PMID: 37400502 Free PMC article.
Multidisciplinary care for patients with HCC: a systematic review and meta-analysis.
Seif El Dahan K, Reczek A, Daher D, Rich NE, Yang JD, Hsiehchen D, Zhu H, Patel MS, Bayona Molano MDP, Sanford N, Gopal P, Parikh ND, Yopp AC, Singal AG. Seif El Dahan K, et al. Among authors: hsiehchen d. Hepatol Commun. 2023 Apr 26;7(5):e0143. doi: 10.1097/HC9.0000000000000143. eCollection 2023 May 1. Hepatol Commun. 2023. PMID: 37102768 Free PMC article.
Cmai: Predicting Antigen-Antibody Interactions from Massive Sequencing Data.
Song B, Wang K, Na S, Yao J, Fattah FJ, von Itzstein MS, Yang DM, Liu J, Xue Y, Liang C, Guo Y, Raman I, Zhu C, Dowell JE, Homsi J, Rashdan S, Yang S, Gwin ME, Hsiehchen D, Gloria-McCutchen Y, Raj P, Bai X, Wang J, Conejo-Garcia J, Xie Y, Gerber DE, Huang J, Wang T. Song B, et al. Among authors: hsiehchen d. bioRxiv [Preprint]. 2024 Jul 12:2024.06.27.601035. doi: 10.1101/2024.06.27.601035. bioRxiv. 2024. PMID: 39005456 Free PMC article. Preprint.
Differences in systemic immune parameters in individuals with lung cancer according to race.
von Itzstein MS, Liu J, Mu-Mosley H, Fattah F, Park JY, SoRelle JA, Farrar JD, Gwin ME, Hsiehchen D, Gloria-McCutchen Y, Wakeland EK, Cole S, Bhalla S, Kainthla R, Puzanov I, Switzer B, Daniels GA, Zakharia Y, Shaheen M, Zhang J, Xie Y, Gerber DE. von Itzstein MS, et al. Among authors: hsiehchen d. bioRxiv [Preprint]. 2024 Jun 10:2024.06.07.597754. doi: 10.1101/2024.06.07.597754. bioRxiv. 2024. PMID: 38915535 Free PMC article. Preprint.
PKD1 mutant clones within cirrhotic livers inhibit steatohepatitis without promoting cancer.
Zhu M, Wang Y, Lu T, Guo J, Li L, Hsieh MH, Gopal P, Han Y, Fujiwara N, Wallace DP, Yu ASL, Fang X, Ransom C, Verschleisser S, Hsiehchen D, Hoshida Y, Singal AG, Yopp A, Wang T, Zhu H. Zhu M, et al. Among authors: hsiehchen d. Cell Metab. 2024 Aug 6;36(8):1711-1725.e8. doi: 10.1016/j.cmet.2024.05.015. Epub 2024 Jun 19. Cell Metab. 2024. PMID: 38901424
Highly variable timing renders immunotherapy efficacy and toxicity impractical biomarkers of one another in clinical practice.
von Itzstein MS, Yang Y, Wang Y, Hsiehchen D, Sheffield TY, Fattah F, Popat V, Ahmed M, Homsi J, Dowell JE, Rashdan S, Lohrey J, Hammers HJ, Hughes RS, Wang T, Xie Y, Gerber DE. von Itzstein MS, et al. Among authors: hsiehchen d. Front Immunol. 2024 Apr 16;15:1351739. doi: 10.3389/fimmu.2024.1351739. eCollection 2024. Front Immunol. 2024. PMID: 38690281 Free PMC article.
Tissue-specific thresholds of mutation burden associated with anti-PD-1/L1 therapy benefit and prognosis in microsatellite-stable cancers.
Muquith M, Espinoza M, Elliott A, Xiu J, Seeber A, El-Deiry W, Antonarakis ES, Graff SL, Hall MJ, Borghaei H, Hoon DSB, Liu SV, Ma PC, McKay RR, Wise-Draper T, Marshall J, Sledge GW, Spetzler D, Zhu H, Hsiehchen D. Muquith M, et al. Among authors: hsiehchen d. Nat Cancer. 2024 Jul;5(7):1121-1129. doi: 10.1038/s43018-024-00752-x. Epub 2024 Mar 25. Nat Cancer. 2024. PMID: 38528112
The phosphatidylserine targeting antibody bavituximab plus pembrolizumab in unresectable hepatocellular carcinoma: a phase 2 trial.
Hsiehchen D, Beg MS, Kainthla R, Lohrey J, Kazmi SM, Khosama L, Maxwell MC, Kline H, Katz C, Hassan A, Kubota N, Siglinsky E, Pillai AK, Youssoufian H, Mockbee C, Culm K, Uhlik M, Benjamin L, Brekken RA, Ahn C, Singal AG, Zhu H, Hoshida Y, Yopp AC. Hsiehchen D, et al. Nat Commun. 2024 Mar 11;15(1):2178. doi: 10.1038/s41467-024-46542-y. Nat Commun. 2024. PMID: 38467639 Free PMC article. Clinical Trial.
pan-MHC and cross-Species Prediction of T Cell Receptor-Antigen Binding.
Han Y, Yang Y, Tian Y, Fattah FJ, von Itzstein MS, Hu Y, Zhang M, Kang X, Yang DM, Liu J, Xue Y, Liang C, Raman I, Zhu C, Xiao O, Dowell JE, Homsi J, Rashdan S, Yang S, Gwin ME, Hsiehchen D, Gloria-McCutchen Y, Pan K, Wu F, Gibbons D, Wang X, Yee C, Huang J, Reuben A, Cheng C, Zhang J, Gerber DE, Wang T. Han Y, et al. Among authors: hsiehchen d. bioRxiv [Preprint]. 2023 Dec 12:2023.12.01.569599. doi: 10.1101/2023.12.01.569599. bioRxiv. 2023. PMID: 38105939 Free PMC article. Preprint.
63 results